Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy

References

• American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabet Care. 2013;36(Suppl 1):S67–S74.
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabet Care. 2023;46(Suppl 1):S19–S40. doi:10.2337/dc23-S002
   PubMedGoogle Scholar
• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional, and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150–161. doi:10.1038/s41574-020-00443-4
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF diabetes atlas. Brussels, Belgium; 2021. Available from: https://www.diabetesatlas.org. Accessed September 12, 2023.
   Google Scholar
• Dayan CM, Besser REJ, Oram RA, et al. Preventing type 1 diabetes in childhood. Science. 2021;373(6554):506–510. doi:10.1126/science.abi4742
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Buckner JH, Herold KC. Immunotherapy: building a bridge to a cure for type 1 diabetes. Science. 2021;373(6554):510–516. doi:10.1126/science.abh1654
   PubMed Web of Science ®Google Scholar
• Tatovic D, Dayan CM. Replacing insulin with immunotherapy: time for a paradigm change in Type 1 diabetes. Diabet Med. 2021;38(12):e14696. doi:10.1111/dme.14696
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82. doi:10.1016/S0140-6736(13)60591-7
   PubMed Web of Science ®Google Scholar
• Esposito S, Toni G, Tascini G, Santi E, Berioli MG, Principi N. Environmental Factors Associated With Type 1 Diabetes. Front Endocrinol. 2019;10:592. doi:10.3389/fendo.2019.00592
   PubMed Web of Science ®Google Scholar
• Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57(4):1084–1092. doi:10.2337/db07-1331
   PubMed Web of Science ®Google Scholar
• Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360(16):1646–1654. doi:10.1056/NEJMra0808284
   PubMed Web of Science ®Google Scholar
• Sharp SA, Rich SS, Wood AR, et al. Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabet Care. 2019;42(2):200–207. doi:10.2337/dc18-1785
   PubMed Web of Science ®Google Scholar
• Warshauer JT, Bluestone JA, Anderson MS. New Frontiers in the Treatment of Type 1 Diabetes. Cell Metab. 2020;31(1):46–61. doi:10.1016/j.cmet.2019.11.017
   PubMed Web of Science ®Google Scholar
• Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 2006;55(12):3238–3245. doi:10.2337/db05-1034
   PubMed Web of Science ®Google Scholar
• Yang L, Zhou ZG, Tan SZ, et al. Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults. Ann N Y Acad Sci. 2008;1150:263–266. doi:10.1196/annals.1447.037
   PubMed Web of Science ®Google Scholar
• Gottlieb PA, Delong T, Baker RL, et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun. 2014;50:38–41. doi:10.1016/j.jaut.2013.10.003
   PubMed Web of Science ®Google Scholar
• Schlosser M, Banga JP, Madec AM, et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia. 2005;48(5):922–930. doi:10.1007/s00125-005-1719-1
   PubMed Web of Science ®Google Scholar
• Rondas D, Crevecoeur I, D’Hertog W, et al. Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes. 2015;64(2):573–586. doi:10.2337/db14-0621
   PubMedGoogle Scholar
• Vermeulen I, Weets I, Asanghanwa M, et al. Contribution of antibodies against IA-2beta and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabet Care. 2011;34(8):1760–1765. doi:10.2337/dc10-2268
   PubMed Web of Science ®Google Scholar
• Denroche HC, Verchere CB. IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants. J Mol Endocrinol. 2018;60(2):R57–R75. doi:10.1530/JME-17-0138
   PubMed Web of Science ®Google Scholar
• Pietropaolo M, Castano L, Babu S, et al. Islet cell autoantigen 69 kD (ICA69). Molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest. 1993;92(1):359–371. doi:10.1172/JCI116574
   PubMed Web of Science ®Google Scholar
• Yang J, Danke NA, Berger D, et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol. 2006;176(5):2781–2789.
   PubMed Web of Science ®Google Scholar
• Purcell AW, Sechi S, DiLorenzo TP. The evolving landscape of autoantigen discovery and characterization in type 1 diabetes. Diabetes. 2019;68(5):879–886. doi:10.2337/dbi18-0066
   PubMed Web of Science ®Google Scholar
• Moriyama H, Abiru N, Paronen J, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A. 2003;100(18):10376–10381. doi:10.1073/pnas.1834450100
   PubMed Web of Science ®Google Scholar
• Doran TM, Morimoto J, Simanski S, et al. Discovery of phosphorylated peripherin as a major humoral autoantigen in type 1 diabetes mellitus. Cell Chem Biol. 2016;23(5):618–628. doi:10.1016/j.chembiol.2016.04.006
   PubMed Web of Science ®Google Scholar
• Nakayama M. Insulin as a key autoantigen in the development of type 1 diabetes. Diabetes Metab Res Rev. 2011;27(8):773–777. doi:10.1002/dmrr.1250
   PubMed Web of Science ®Google Scholar
• Strollo R, Vinci C, Man YKS, et al. Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes. Diabetologia. 2023;66(1):132–146. doi:10.1007/s00125-022-05812-4
   PubMed Web of Science ®Google Scholar
• Yang ML, Kibbey RG, Mamula MJ. Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes. Front Immunol. 2022;13:1028130. doi:10.3389/fimmu.2022.1028130
   PubMed Web of Science ®Google Scholar
• McLaughlin KA, Richardson CC, Ravishankar A, et al. Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes. 2016;65(6):1690–1698. doi:10.2337/db15-1058
   PubMed Web of Science ®Google Scholar
• Gonzalez-Duque S, Azoury ME, Colli ML, et al. Conventional and neo-antigenic peptides presented by beta cells are targeted by circulating naive CD8+ T cells in type 1 diabetic and healthy donors. Cell Metab. 2018;28(6):946–960 e946. doi:10.1016/j.cmet.2018.07.007
   PubMed Web of Science ®Google Scholar
• Gomes KF, Semzezem C, Batista R, et al. Importance of zinc transporter 8 autoantibody in the diagnosis of type 1 diabetes in Latin Americans. Scientific Reports. 2017;7(1):207.
   PubMedGoogle Scholar
• Rodriguez-Fernandez S, Almenara-Fuentes L, Perna-Barrull D, Barneda B, Vives-Pi M A century later, still fighting back: antigen-specific immunotherapies for type 1 diabetes. Immunol Cell Biol. 2021;99:461–474.
   PubMed Web of Science ®Google Scholar
• Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabet Care. 2015;38(10):1964–1974. doi:10.2337/dc15-1419
   PubMed Web of Science ®Google Scholar
• Katsarou A, Gudbjornsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3(1):17016. doi:10.1038/nrdp.2017.16
   PubMedGoogle Scholar
• Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473–2479. doi:10.1001/jama.2013.6285
   PubMed Web of Science ®Google Scholar
• Ahmed S, Cerosaletti K, James E, et al. Standardizing T-cell biomarkers in type 1 diabetes: challenges and recent advances. Diabetes. 2019;68(7):1366–1379. doi:10.2337/db19-0119
   PubMed Web of Science ®Google Scholar
• Kasmani MY, Ciecko AE, Brown AK, et al. Autoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage. Life Sci Alliance. 2022;5(10):e202201503. doi:10.26508/lsa.202201503
   PubMed Web of Science ®Google Scholar
• Babon JA, DeNicola ME, Blodgett DM, et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med. 2016;22(12):1482–1487. doi:10.1038/nm.4203
   PubMed Web of Science ®Google Scholar
• Michels AW, Landry LG, McDaniel KA, et al. Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes. Diabetes. 2017;66(3):722–734. doi:10.2337/db16-1025
   PubMed Web of Science ®Google Scholar
• Delong T, Wiles TA, Baker RL, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016;351(6274):711–714. doi:10.1126/science.aad2791
   PubMed Web of Science ®Google Scholar
• Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13(11):674–686. doi:10.1038/nrendo.2017.99
   PubMed Web of Science ®Google Scholar
• Buzzetti R, Maddaloni E, Gaglia J, Leslie RD, Wong FS, Boehm BO. Adult-onset autoimmune diabetes. Nat Rev Dis Primers. 2022;8(1):63. doi:10.1038/s41572-022-00390-6
   PubMedGoogle Scholar
• Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69(10):2037–2047. doi:10.2337/dbi20-0017
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice C. 3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes-2022. Diabet Care. 2022;45(Suppl 1):S39–S45. doi:10.2337/dc22-S003
   PubMedGoogle Scholar
• Andersen MK, Lundgren V, Turunen JA, et al. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years. Diabet Care. 2010;33(9):2062–2064. doi:10.2337/dc09-2188
   PubMed Web of Science ®Google Scholar
• Jorns A, Wedekind D, Jahne J, Lenzen S. Pancreas Pathology of Latent Autoimmune Diabetes in Adults (LADA) in patients and in a LADA rat model compared with type 1 diabetes. Diabetes. 2020;69(4):624–633. doi:10.2337/db19-0865
   PubMed Web of Science ®Google Scholar
• Cousminer DL, Ahlqvist E, Mishra R, et al. First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabet Care. 2018;41(11):2396–2403. doi:10.2337/dc18-1032
   PubMed Web of Science ®Google Scholar
• Mishra R, Akerlund M, Cousminer DL, et al. Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diabet Care. 2020;43(2):418–425. doi:10.2337/dc19-0986
   PubMed Web of Science ®Google Scholar
• Andersen MK. New insights into the genetics of latent autoimmune diabetes in adults. Curr Diab Rep. 2020;20(9):43. doi:10.1007/s11892-020-01330-y
   PubMed Web of Science ®Google Scholar
• Pettersen E, Skorpen F, Kvaloy K, Midthjell K, Grill V. Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trondelag Health Study. Diabetes. 2010;59(1):302–310. doi:10.2337/db09-0923
   PubMed Web of Science ®Google Scholar
• Liu L, Li X, Xiang Y, et al. Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3). Diabet Care. 2015;38(1):16–21. doi:10.2337/dc14-1770
   PubMed Web of Science ®Google Scholar
• Hjort R, Ahlqvist E, Carlsson PO, et al. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study. Diabetologia. 2018;61(6):1333–1343. doi:10.1007/s00125-018-4596-0
   PubMed Web of Science ®Google Scholar
• Zaharia OP, Bobrov P, Strassburger K, et al. Metabolic characteristics of recently diagnosed adult-onset autoimmune diabetes mellitus. J Clin Endocrinol Metab. 2018;103(2):429–437. doi:10.1210/jc.2017-01706
   PubMed Web of Science ®Google Scholar
• Dong F, Yang G, Pan HW, et al. The association of PTPN22 rs2476601 polymorphism and CTLA-4 rs231775 polymorphism with LADA risks: a systematic review and meta-analysis. Acta Diabetol. 2014;51(5):691–703. doi:10.1007/s00592-014-0613-z
   PubMed Web of Science ®Google Scholar
• Ramu D, Perumal V, Paul SFD. Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: a meta-analysis. J Diabetes. 2019;11(6):484–496. doi:10.1111/1753-0407.12879
   PubMed Web of Science ®Google Scholar
• Lofvenborg JE, Ahlqvist E, Alfredsson L, et al. Consumption of red meat, genetic susceptibility, and risk of LADA and type 2 diabetes. Eur J Nutr. 2021;60(2):769–779. doi:10.1007/s00394-020-02285-2
   PubMed Web of Science ®Google Scholar
• Hjort L, Novakovic B, Grunnet LG, et al. Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child’s epigenome and later risk of disease. Lancet Diabetes Endocrinol. 2019;7(10):796–806. doi:10.1016/S2213-8587(19)30078-6
   PubMed Web of Science ®Google Scholar
• Carlsson S. Environmental (Lifestyle) Risk Factors for LADA. Curr Diabetes Rev. 2019;15(3):178–187. doi:10.2174/1573399814666180716150253
   PubMed Web of Science ®Google Scholar
• Lofvenborg JE, Andersson T, Carlsson PO, et al. Sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Eur J Endocrinol. 2016;175(6):605–614. doi:10.1530/EJE-16-0376
   PubMed Web of Science ®Google Scholar
• Rasouli B, Andersson T, Carlsson PO, et al. Alcohol and the risk for latent autoimmune diabetes in adults: results based on Swedish ESTRID study. Eur J Endocrinol. 2014;171(5):535–543. doi:10.1530/EJE-14-0403
   PubMed Web of Science ®Google Scholar
• Fang Y, Zhang C, Shi H, et al. Characteristics of the Gut microbiota and metabolism in patients with latent autoimmune diabetes in adults: a case-control study. Diabet Care. 2021;44(12):2738–2746. doi:10.2337/dc20-2975
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11(5):289–297. doi:10.1038/nrendo.2015.8
   PubMed Web of Science ®Google Scholar
• Gearty SV, Dundar F, Zumbo P, et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature. 2022;602(7895):156–161. doi:10.1038/s41586-021-04248-x
   PubMed Web of Science ®Google Scholar
• Tatovic D, McAteer MA, Barry J, et al. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes. Immunother Adv. 2022;2(1):ltac002. doi:10.1093/immadv/ltac002
   PubMedGoogle Scholar
• Villalba A, Rodriguez-Fernandez S, Perna-Barrull D, et al. Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes. Sci Rep. 2020;10(1):18927. doi:10.1038/s41598-020-76041-1
   PubMed Web of Science ®Google Scholar
• Yue T, Sun F, Wang F, et al. MBD2 acts as a repressor to maintain the homeostasis of the Th1 program in type 1 diabetes by regulating the STAT1-IFN-gamma axis. Cell death and differentiation. 2022;29(1):218–229.
   PubMed Web of Science ®Google Scholar
• Cai EP, Ishikawa Y, Zhang W, et al. Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. Nat Metab. 2020;2(9):934–945. doi:10.1038/s42255-020-0254-1
   PubMedGoogle Scholar
• Ekman I, Ihantola EL, Viisanen T, et al. Circulating CXCR5(-)PD-1(hi) peripheral T helper cells are associated with progression to type 1 diabetes. Diabetologia. 2019;62(9):1681–1688. doi:10.1007/s00125-019-4936-8
   PubMed Web of Science ®Google Scholar
• Yin W, Luo S, Xiao Z, Zhang Z, Liu B, Zhou Z. Latent autoimmune diabetes in adults: a focus on beta-cell protection and therapy. Front Endocrinol. 2022;13:959011. doi:10.3389/fendo.2022.959011
   PubMed Web of Science ®Google Scholar
• Liu YF, Powrie J, Arif S, et al. Immune and metabolic effects of antigen-specific immunotherapy using multiple beta-cell peptides in type 1 diabetes. Diabetes. 2022;71(4):722–732. doi:10.2337/db21-0728
   PubMed Web of Science ®Google Scholar
• Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603–613. doi:10.1056/NEJMoa1902226
   PubMed Web of Science ®Google Scholar
• Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with Abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412–419. doi:10.1016/S0140-6736(11)60886-6
   PubMed Web of Science ®Google Scholar
• Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes. 2011;12(7):656–667. doi:10.1111/j.1399-5448.2011.00761.x
   PubMed Web of Science ®Google Scholar
• Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905–1915. doi:10.1016/S0140-6736(13)60023-9
   PubMed Web of Science ®Google Scholar
• Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabet Care. 2009;32(7):1244–1249. doi:10.2337/dc09-0054
   PubMed Web of Science ®Google Scholar
• Tavira B, Barcenilla H, Wahlberg J, Achenbach P, Ludvigsson J, Casas R. Intralymphatic glutamic acid decarboxylase-alum administration induced Th2-like-specific immunomodulation in responder patients: a pilot clinical trial in type 1 diabetes. J Diabetes Res. 2018;2018:9391845. doi:10.1155/2018/9391845
   PubMed Web of Science ®Google Scholar
• Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(8):502–514. doi:10.1016/S2213-8587(21)00139-X
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabet Care. 2014;37(2):453–459. doi:10.2337/dc13-0626
   PubMed Web of Science ®Google Scholar
• Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487–497. doi:10.1016/S0140-6736(11)60931-8
   PubMed Web of Science ®Google Scholar
• Haller MJ, Long SA, Blanchfield JL, et al. Low-dose anti-thymocyte globulin preserves C-Peptide, Reduces HbA(1c), and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data. Diabetes. 2019;68(6):1267–1276. doi:10.2337/db19-0057
   PubMed Web of Science ®Google Scholar
• Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabet Care. 2010;33(4):826–832. doi:10.2337/dc09-1349
   PubMed Web of Science ®Google Scholar
• Greenbaum CJ, Serti E, Lambert K, et al. IL-6 receptor blockade does not slow beta cell loss in new-onset type 1 diabetes. JCI Insight. 2021;6(21):e150074.
   PubMed Web of Science ®Google Scholar
• Faustman DL, Lee A, Hostetter ER, et al. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Rep Med. 2022;3(9):100728. doi:10.1016/j.xcrm.2022.100728
   PubMedGoogle Scholar
• Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a Phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295–305. doi:10.1016/S2213-8587(13)70113-X
   PubMed Web of Science ®Google Scholar
• Rios-Rios WJ, Sosa-Luis SA, Torres-Aguilar H. Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes. World J Diabetes. 2021;12(5):603–615. doi:10.4239/wjd.v12.i5.603
   PubMed Web of Science ®Google Scholar
• Quattrin T, Haller MJ, Steck AK, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383(21):2007–2017. doi:10.1056/NEJMoa2006136
   PubMed Web of Science ®Google Scholar
• Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285–3296. doi:10.1172/JCI81722
   PubMed Web of Science ®Google Scholar
• von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(4):212–224. doi:10.1016/S2213-8587(21)00019-X
   PubMed Web of Science ®Google Scholar
• Beran D, Abidha C, Adler A, et al. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023;11(2):78–80. doi:10.1016/S2213-8587(22)00384-9
   PubMedGoogle Scholar
• White PC, Adhikari S, Grishman EK, Sumpter KM. A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus. Pediatr Diabetes. 2018;19(4):788–793. doi:10.1111/pedi.12634
   PubMed Web of Science ®Google Scholar
• Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J, Di A. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes. 2018;19(3):410–419. doi:10.1111/pedi.12611
   PubMed Web of Science ®Google Scholar
• Mathieu C, Lahesmaa R, Bonifacio E, Achenbach P, Tree T. Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia. 2018;61(11):2252–2258. doi:10.1007/s00125-018-4726-8
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Routray I, Elluru S, et al. Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial. Future Sci OA. 2020;6(7):FSO604. doi:10.2144/fsoa-2020-0078
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–2152. doi:10.1056/NEJMoa0904452
   PubMed Web of Science ®Google Scholar
• Dong S, Hiam-Galvez KJ, Mowery CT, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021;6(18). doi:10.1172/jci.insight.147474
   Web of Science ®Google Scholar
• Nikolic T, Zwaginga JJ, Uitbeijerse BS, et al. Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes. Lancet Diabetes Endocrinol. 2020;8(6):470–472. doi:10.1016/S2213-8587(20)30104-2
   PubMed Web of Science ®Google Scholar
• Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005;19(4):238–246. doi:10.1016/j.jdiacomp.2004.12.003
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet β cell function in adult‐onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2005;21(2):203–208. doi:10.1002/dmrr.503
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract. 2009;83(1):54–60. doi:10.1016/j.diabres.2008.09.044
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yan X, Wu C, et al. Adding vitamin D3 to the dipeptidyl peptidase‐4 inhibitor saxagliptin has the potential to protect β‐cell function in LADA patients: a 1‐year pilot study. Diabetes Metab Res Rev. 2020;36(5):e3298. doi:10.1002/dmrr.3298
   PubMed Web of Science ®Google Scholar